
Diallo Igwe Duniver
Examiner (ID: 18609, Phone: (571)270-1794 , Office: P/3742 )
| Most Active Art Unit | 3742 |
| Art Unit(s) | 3742, 3761 |
| Total Applications | 325 |
| Issued Applications | 138 |
| Pending Applications | 1 |
| Abandoned Applications | 186 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18567130
[patent_doc_number] => 20230257459
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN
[patent_app_type] => utility
[patent_app_number] => 18/176934
[patent_app_country] => US
[patent_app_date] => 2023-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20046
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -4
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176934
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/176934 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING AN IMMUNE CHECKPOINT INHIBITOR ANTIBODY AND A FUSION PROTEIN COMPRISING AN IL-2 MUTANT AND A CD80 EXTRACELLULAR DOMAIN | Feb 28, 2023 | Pending |
Array
(
[id] => 18789136
[patent_doc_number] => 20230377764
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-23
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 18/164164
[patent_app_country] => US
[patent_app_date] => 2023-02-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18164164
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/164164 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH ECM-AFFINITY PEPTIDES LINKED TO IMMUNOTHERAPEUTIC ANTIBODIES | Feb 2, 2023 | Pending |
Array
(
[id] => 18391411
[patent_doc_number] => 20230159629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/096349
[patent_app_country] => US
[patent_app_date] => 2023-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18096349
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/096349 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION | Jan 11, 2023 | Pending |
Array
(
[id] => 18391411
[patent_doc_number] => 20230159629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION
[patent_app_type] => utility
[patent_app_number] => 18/096349
[patent_app_country] => US
[patent_app_date] => 2023-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29849
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18096349
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/096349 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION | Jan 11, 2023 | Pending |
Array
(
[id] => 18531117
[patent_doc_number] => 20230236188
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => METHODS OF DIAGNOSING AND TREATING LUPUS
[patent_app_type] => utility
[patent_app_number] => 18/152056
[patent_app_country] => US
[patent_app_date] => 2023-01-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14471
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 33
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152056
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/152056 | METHODS OF DIAGNOSING AND TREATING LUPUS | Jan 8, 2023 | Pending |
Array
(
[id] => 18529939
[patent_doc_number] => 20230235006
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => Masked Cytokine Polypeptides
[patent_app_type] => utility
[patent_app_number] => 18/089754
[patent_app_country] => US
[patent_app_date] => 2022-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 157461
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18089754
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/089754 | Masked IL-2-Fc fusion polypeptides | Dec 27, 2022 | Issued |
Array
(
[id] => 18496091
[patent_doc_number] => 20230218634
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/088400
[patent_app_country] => US
[patent_app_date] => 2022-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15633
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18088400
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/088400 | METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY | Dec 22, 2022 | Pending |
Array
(
[id] => 18484984
[patent_doc_number] => 20230212299
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer
[patent_app_type] => utility
[patent_app_number] => 18/069511
[patent_app_country] => US
[patent_app_date] => 2022-12-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 63665
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18069511
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/069511 | Anti-CSF1R Antibody and Anti-PD-1 Antibody Combination Therapy for Cancer | Dec 20, 2022 | Pending |
Array
(
[id] => 18468911
[patent_doc_number] => 20230203195
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/068694
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13092
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068694
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068694 | ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF | Dec 19, 2022 | Pending |
Array
(
[id] => 18468911
[patent_doc_number] => 20230203195
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/068694
[patent_app_country] => US
[patent_app_date] => 2022-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13092
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 173
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068694
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068694 | ANTI-VWF D'D3 SINGLE-DOMAIN ANTIBODIES AND POLYPEPTIDES COMPRISING THEREOF | Dec 19, 2022 | Pending |
Array
(
[id] => 18436014
[patent_doc_number] => 20230183308
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => PROPROTEINS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/068104
[patent_app_country] => US
[patent_app_date] => 2022-12-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21228
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18068104
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/068104 | PROPROTEINS AND METHODS OF USE THEREOF | Dec 18, 2022 | Pending |
Array
(
[id] => 18626710
[patent_doc_number] => 20230285513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => TREATMENT OF CANCER WITH IMMUNE STIMULATORS
[patent_app_type] => utility
[patent_app_number] => 18/064793
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064793
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064793 | TREATMENT OF CANCER WITH IMMUNE STIMULATORS | Dec 11, 2022 | Pending |
Array
(
[id] => 18626710
[patent_doc_number] => 20230285513
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => TREATMENT OF CANCER WITH IMMUNE STIMULATORS
[patent_app_type] => utility
[patent_app_number] => 18/064793
[patent_app_country] => US
[patent_app_date] => 2022-12-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19179
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18064793
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/064793 | TREATMENT OF CANCER WITH IMMUNE STIMULATORS | Dec 11, 2022 | Pending |
Array
(
[id] => 18657712
[patent_doc_number] => 20230303659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => INTRATUMORAL VACCINATION
[patent_app_type] => utility
[patent_app_number] => 18/062146
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062146
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062146 | INTRATUMORAL VACCINATION | Dec 5, 2022 | Abandoned |
Array
(
[id] => 18657712
[patent_doc_number] => 20230303659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => INTRATUMORAL VACCINATION
[patent_app_type] => utility
[patent_app_number] => 18/062146
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062146
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062146 | INTRATUMORAL VACCINATION | Dec 5, 2022 | Abandoned |
Array
(
[id] => 18657712
[patent_doc_number] => 20230303659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => INTRATUMORAL VACCINATION
[patent_app_type] => utility
[patent_app_number] => 18/062146
[patent_app_country] => US
[patent_app_date] => 2022-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18062146
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/062146 | INTRATUMORAL VACCINATION | Dec 5, 2022 | Abandoned |
Array
(
[id] => 18649502
[patent_doc_number] => 20230295318
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDES
[patent_app_type] => utility
[patent_app_number] => 18/057591
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057591
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057591 | ANTI-MULLERIAN HORMONE RECEPTOR BINDING PEPTIDES | Nov 20, 2022 | Pending |
Array
(
[id] => 18391423
[patent_doc_number] => 20230159641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/057465
[patent_app_country] => US
[patent_app_date] => 2022-11-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35032
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18057465
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/057465 | ANTI-PD-L1 ANTIBODIES AND DIAGNOSTIC USES THEREOF | Nov 20, 2022 | Pending |
Array
(
[id] => 18550769
[patent_doc_number] => 20230248769
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/051492
[patent_app_country] => US
[patent_app_date] => 2022-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46843
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051492
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051492 | IMMUNOGENIC PEPTIDES SPECIFIC TO BCMA AND TACI ANTIGENS FOR TREATMENT OF CANCER | Oct 30, 2022 | Pending |
Array
(
[id] => 18597225
[patent_doc_number] => 20230272019
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => FUNGAL GLYCAN BINDING PROTEIN WHICH POSSESSES ANTIVIRAL AND ANTICANCER ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 18/050485
[patent_app_country] => US
[patent_app_date] => 2022-10-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16893
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18050485
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/050485 | FUNGAL GLYCAN BINDING PROTEIN WHICH POSSESSES ANTIVIRAL AND ANTICANCER ACTIVITY | Oct 27, 2022 | Pending |